Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Insights

- PMLiVE

AZ and MSD launch ‘Never Miss’ for prostate cancer awareness

Prostate cancer is often symptomless and is the second most common cancer in men globally

- PMLiVE

Cancer Research Horizons and the Karolinska Institutet announce five-year strategic partnership

The collaboration will aim to accelerate the translation of cancer research into clinical practice

- PMLiVE

AstraZeneca to acquire Neogene Therapeutics in $320m deal

The agreement will build the company’s pipeline of cell-based cancer treatments

- PMLiVE

Medscape Medical Affairs Celebrate a Double Win at the PMEAs

Last night the Medscape Medical Affairs team gathered in London for the Pharmaceutical Market Excellence Awards (PMEAs) where their entry, Transatlantic Exchanges: Driving Therapeutic Innovation in Oncology for the Benefit of...

Medscape Medical Affairs

- PMLiVE

Precision medicine trial opens for patients with rare cancers

Rare cancers make up 22% of cancers that are diagnosed globally each year, more than any single type of cancer

- PMLiVE

Cancer Research Horizons and Newcastle University extend alliance with Astex

The agreement will extend the current alliance between the three parties by a further five years

- PMLiVE

ICR and The Royal Marsden reveal plans to ‘disrupt’ cancer ecosystems

The researchers aim to double survival for people with advanced cancer within a decade

- PMLiVE

BeiGene’s Brukinsa receives EC approval for chronic lymphocytic leukaemia

The drug showed better results than Imbruvica, a current standard of care treatment

regeneron headquarters

Regeneron and CytomX partner to create conditional bispecific cancer therapies

CytomX is set to receive an upfront payment of $30m as well as milestones of up to $2bn

ESMO’s New Focus on Cancer Prevention

During ESMO 2022 in Paris, John Whyte, chief medical officer at WebMD was joined by Fabrice André, MD, PhD, Chair of the scientific committee at the European Society for Medical Oncology (ESMO),...

Medscape Education Global

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza

The treatments are for use in prostate, biliary tract and advanced gastric cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links